Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
The patients signed the written informed consent
Women aged 18-70.
The pathologic diagnosis of recurrent metastatic triple negative breast cancer ［ER-negative(IHC\<1%), PR-negative(IHC\<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］.
At least one measuring lesion that conforms to RECIST v1.1 standard.
The number of chemotherapy lines in the metastatic phase was \<3 line.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
Have a life expectancy of at least 12 weeks.
Female Subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 3 months after the last dose of study treatment.
The patients can swallow pills.
The results of patients' blood tests are as follows: • Hb≥90g/L; • Plt≥90E+9/L; • Neutrophils≥1.5E+9/L; • ALT and AST ≤ triple of normal upper limit; • TBIL ≤ 1.5 times of normal upper limit; • Creatinine ≤ 1.5 times of normal upper limit.
You may not be if
The subjects had any history of autoimmune disease or any use of systemic glucocorticoid or immunosuppressive medications.
Subjects with severe allergic reactions to other monoclonal antibodies.
The subjects had a central nervous system metastases with clinical symptoms.
History of hypertension and antihypertensive medications are not well controlled.
A heart condition or disease that is not well controlled.
Subjects had active infections or recent treatment with a systemic immunostimulatory agent (received within the previous 4 weeks).
Other clinical trials of drugs were used in the first four weeks of the first medication.
Subjects with treatment history of anti-angiogenesis drugs or check-point inhibitors.
Clareo Health | A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC
